Pierre A. MORGON

CEO of MRGN Advisors, Executive Vice President, Portfolio Strategy and Supranational Affairs at CanSino Biologics and Regional Partner for Switzerland at Merieux Equity Partners.
He is Chairman of the Boards of Theradiag, Eurocine Vaccines, MYCB1, Adiposs, Kupando and Health Technologies Holding, as well as Non-Executive Director to the Boards of Vaccitech, Univercells, Amoeba and Limula.
 
Pierre has over 35 years of experience in the global pharmaceutical and biological industry, both at the helm of operations (from business unit head to general manager and CEO) and in marketing and commercial positions (from product marketing at country level to global marketing strategy).  Through these local and global positions, he has acquired direct experience with blockbuster products in diverse markets (primary care, specialty care, hospital, vaccines, and biotechnology), geographies (US, Europe, Japan, China, India, Emerging Markets) and organizations.
 
He spent 2 years at ICI-Pharma, followed by 8 years at Synthelabo, then a division of L’Oreal, followed by 6 years at Aventis Pasteur. Then he had diversified C-level and senior executive management experiences at Yamanouchi Pharma, BMS, Drug Abuse Sciences, Schering-Plough, Bio Alliance Pharma, Sanofi Pasteur, Cegedim and AJ Biologics.
 
He is a lecturer in several MBA programs and in life science conferences, and at the Mass Challenge incubator in Switzerland where he is also a mentor for start-up life sciences companies.
 
He holds a Doctorate of Pharmacy, a Master in Business Law and a MBA, and he is an alumnus of INSEAD and IMD.